CompletedPhase 3

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

NCT01646320

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

University Of Alabama At Birmingham

Birmingham, Alabama, United States

+65 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2012-09
Enrollment: 320 participants
Sponsor: AstraZeneca
Purpose: treatment

Locations (66)

University Of Alabama At BirminghamBirmingham, Alabama, United States
Clinical Research Advantage Inc/Desert Clinical Research LlcMesa, Arizona, United States
Clinical Research Advantage, Inc.Phoenix, Arizona, United States
Elite Clinical Studies, LlcPhoenix, Arizona, United States
Arkansas Clinical ResearchLittle Rock, Arkansas, United States
Torrance Clinical Research Institute Inc.Lomita, California, United States
Randall G. Shue, Do, Inc.Los Angeles, California, United States
National Research InstituteLos Angeles, California, United States
Diabetes Medical Center Of CaliforniaNorthridge, California, United States
Cassidy Medical Group/Clinical Research AdvantageVista, California, United States
Palm Springs Research InstituteHialeah, Florida, United States
Fpa Clinical ResearchKissimmee, Florida, United States
International Research Associates, LlcMiami, Florida, United States
Omega Research Consultants, LlcOrlando, Florida, United States
Compass Research East, LlcOviedo, Florida, United States
Palm Harbor Medical AssociatesPalm Harbor, Florida, United States
Cedar Crosse Research CenterChicago, Illinois, United States
Clinical Research AdvantageEvansville, Indiana, United States
Associated Internal Medicine SpecialistsBattle Creek, Michigan, United States
Jackson ClinicRolling Fork, Mississippi, United States
Premier ResearchTrenton, New Jersey, United States
Metrolina Internal MedicineCharlotte, North Carolina, United States
Sterling Research Grp, Ltd.Cincinnati, Ohio, United States
Endocrine AssociatesHouston, Texas, United States
Sam Clinical Research CenterSan Antonio, Texas, United States
Tidewater Integrated Medical ResearchVirginia Beach, Virginia, United States
Local InstitutionBroumov, Czechia
Local InstitutionPardubice, Czechia
Local InstitutionPrague, Czechia
Local InstitutionPrague, Czechia
Local InstitutionPribram V, Czechia
Local InstitutionAguascalientes, Aguascalientes, Mexico
Local InstitutionGuadalajara, Jalisco, Mexico
Local InstitutionZapopan, Jalisco, Mexico
Local InstitutionZapopan, Jalisco, Mexico
Local InstitutionMonterrey, Nuevo León, Mexico
Local InstitutionMonterrey, Nuevo León, Mexico
Local InstitutionBialystok, Poland
Local InstitutionKrakow, Poland
Local InstitutionRuda Śląska, Poland
Local InstitutionWarsaw, Poland
Local InstitutionWarsaw, Poland
Local InstitutionWarsaw, Poland
Local InstitutionŻory, Poland
Clinical Research Puerto RicoSan Juan, Puerto Rico
Local InstitutionBucharest, Bucharest, Romania
Local InstitutionBucharest, Romania
Local InstitutionConstanța, Romania
Local InstitutionCraiova, Romania
Local InstitutionGalati, Romania
Local InstitutionPloieşti, Romania
Local InstitutionKursk, Russia
Local InstitutionMoscow, Russia
Local InstitutionSaint Petersburg, Russia
Local InstitutionSaint Petersburg, Russia
Local InstitutionSaint Petersburg, Russia
Local InstitutionSaint Petersburg, Russia
Local InstitutionSaint Petersburg, Russia
Local InstitutionSaint Petersburg, Russia
Local InstitutionYaroslaval, Russia
Local InstitutionPortsmouth, Hants, United Kingdom
Local InstitutionNewport, Isle of Wight, United Kingdom
Local InstitutionLiverpool, Merseyside, United Kingdom
Local InstitutionChippenham, Wiltshire, United Kingdom
Local InstitutionBedfordshire, United Kingdom
Local InstitutionLondon, United Kingdom